GRI Bio, Inc. (GRI): Nasdaq/NYSE listing notice — GRI BIO receives Nasdaq delisting notice for stockholders' equity deficiency

GRI Bio, Inc.

Nasdaq notified GRI BIO of non-compliance with minimum stockholders' equity requirement (Listing Rule 5550(b)(1)).
As of September 30, 2025, stockholders' equity fell below the required $2.5M threshold.
Company has 45 days (until January 10, 2026) to submit a plan to regain compliance.
If plan accepted, Nasdaq may grant up to 180 additional calendar days to cure the deficiency.
Failure to regain compliance or rejection of plan may lead to delisting; company can appeal.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

GRI Bio, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

November 26, 2025, the Company received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities of less than $35,000,000 and a

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

GRI Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001824293-25-000155

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.